Zetia Manufacturer Copay Program: How to Lower Your Ezetimibe Costs in 2026

Does Zetia Still Have a Manufacturer Copay Program?

No. Merck discontinued the branded Zetia copay card after multiple generic ezetimibe products entered the market beginning in December 2016. The original program reduced brand-name copays to as low as $0 for commercially insured patients, but it no longer accepts new enrollments as of 2026.

Why the Program Ended

When the FDA approved the first generic ezetimibe (manufactured by Glenmark Pharmaceuticals and Par Pharmaceutical), the commercial rationale for a brand copay card disappeared. Generic competition drove the average cash price from roughly $350 per month for brand Zetia down to $4 to $15 for generic ezetimibe at most retail pharmacies 1. This price collapse made copay subsidies unnecessary for the vast majority of patients.

What Replaced the Copay Card

Merck shifted its patient support toward the Merck Helps Patient Assistance Program, which provides free medications (including ezetimibe where applicable) to patients who are uninsured, lack prescription drug coverage, and meet income thresholds. Applicants generally must demonstrate a household income at or below 400% of the Federal Poverty Level 2.

How Much Does Generic Ezetimibe Cost Without Insurance?

Generic ezetimibe 10 mg (the only available dose) has an average cash price of $10 to $15 for a 30-day supply, though prices vary by pharmacy. Some large retailers price it even lower. Costco, Walmart, and Mark Cuban's Cost Plus Drugs have listed 30-tablet supplies for under $5 in recent months.

Retail Pharmacy Price Comparison

Prices shift quarterly, but a general snapshot for 30 tablets of ezetimibe 10 mg in 2026 looks like this:

| Pharmacy Type | Typical Cash Price | With Discount Card | |---|---|---| | Big-box (Costco, Walmart) | $4 to $7 | $3.50 to $5 | | Chain (CVS, Walgreens) | $12 to $18 | $6 to $10 | | Independent | $10 to $25 | $5 to $12 | | Mail-order (90-day) | $8 to $20 | $7 to $15 |

These figures reflect a drug that has reached full generic maturity. The FDA Orange Book lists more than a dozen approved generic manufacturers for ezetimibe, which keeps competition high and prices low.

When Brand Zetia Might Still Be Dispensed

A small number of prescriptions are still written as "brand medically necessary" or "dispense as written." If your pharmacist fills brand Zetia, expect to pay $300 to $400 per month. Ask your prescriber whether a generic substitution is acceptable. For most patients, the FDA has rated generic ezetimibe as therapeutically equivalent (AB-rated), meaning it delivers the same clinical effect 3.

How to Get Ezetimibe at the Lowest Possible Price

Several strategies can reduce your cost to nearly zero. The right approach depends on your insurance status and income level.

Strategy 1: Use a Pharmacy Discount Card

Free discount platforms (GoodRx, RxSaver, SingleCare, Amazon Pharmacy) negotiate preset prices with pharmacies. No insurance is required. For ezetimibe, these cards routinely bring the price to $3.50 to $8. You hand the card to your pharmacist at checkout, and the discount applies immediately. These are not insurance products. They do not count toward your deductible.

Strategy 2: Check Your Insurance Formulary

Most commercial insurers, Medicare Part D plans, and Medicaid programs list generic ezetimibe on Tier 1 (preferred generic). Tier 1 copays range from $0 to $10 depending on your specific plan. A 2023 analysis of Medicare Part D formularies found that 97% of standalone prescription drug plans covered ezetimibe without prior authorization 4. If your plan requires a higher copay, a discount card may actually be cheaper than using your insurance.

Strategy 3: Apply for Patient Assistance

If you are uninsured and cannot afford the generic price, two pathways exist. Merck Helps covers qualifying patients, though the program prioritizes brand-name Merck products. NeedyMeds and RxAssist maintain searchable databases of patient assistance programs (PAPs) for generic drugs, and some generic manufacturers run their own small PAPs. Income documentation is typically required.

Strategy 4: Ask About 90-Day Fills

Switching from a 30-day to a 90-day supply often reduces your per-tablet cost. Many insurance plans and pharmacy benefit managers offer 90-day fills through mail-order at the cost of two monthly copays. For a Tier 1 generic like ezetimibe, this can mean paying $6 to $8 for a full quarter's supply rather than $3 to $5 three separate times.

Insurance Coverage for Ezetimibe in 2026

Ezetimibe has one of the broadest insurance coverage profiles of any cholesterol medication. Its low acquisition cost makes it easy for payers to include on formularies.

Commercial Insurance

Nearly all employer-sponsored and marketplace (ACA) plans cover generic ezetimibe at Tier 1. Prior authorization is almost never required. Step therapy restrictions are uncommon because ezetimibe is already positioned as an add-on to statin therapy rather than a first-line agent. The 2018 AHA/ACC cholesterol guideline recommends adding ezetimibe for patients who do not reach sufficient LDL-C reduction on maximally tolerated statin doses alone 5.

Medicare Part D

All Medicare Part D plans are required to cover at least one cholesterol absorption inhibitor. In practice, generic ezetimibe is universally covered. During the coverage gap (the "donut hole"), enrollees in 2026 pay 25% of the negotiated price for generic drugs. For ezetimibe at a negotiated rate of $8, that amounts to roughly $2.

Medicaid

State Medicaid programs cover generic ezetimibe in all 50 states, typically with copays of $0 to $3. Some states classify it as a preferred drug, while others list it on a non-preferred tier that may require trying a statin first. If you receive Medicaid and are told ezetimibe is not covered, ask your prescriber to submit a prior authorization documenting prior statin therapy 6.

VA and TRICARE

The Department of Veterans Affairs national formulary includes ezetimibe. VA copays for Tier 1 generics are $5 for a 30-day supply (2026 rates). TRICARE formulary covers ezetimibe at the generic copay tier, which is $14 for a 90-day retail fill or $0 for military pharmacy fills 7.

The Clinical Case for Ezetimibe Access

Ezetimibe blocks cholesterol absorption in the small intestine through the Niemann-Pick C1-Like 1 (NPC1L1) transporter. It reduces LDL-C by approximately 18% to 25% as monotherapy. But its largest outcome benefit was demonstrated as statin add-on therapy.

IMPROVE-IT Trial Results

The IMPROVE-IT trial (N=18,144) randomized post-acute coronary syndrome patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. Over a median follow-up of 6 years, the ezetimibe group achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo group. The primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the ezetimibe group versus 34.7% of the placebo group (HR 0.936, 95% CI 0.89 to 0.99, P=0.016) 8.

This was the first trial to prove that a non-statin LDL-lowering drug added to statin therapy reduces cardiovascular events. Dr. Christopher Cannon, lead investigator of IMPROVE-IT, stated: "This trial validates the concept that lower is better for LDL cholesterol, and that achieving very low levels with combination therapy translates to fewer heart attacks and strokes" 8.

Guideline Positioning

The 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol recommends ezetimibe as the preferred first add-on therapy for patients on maximally tolerated statins who need additional LDL-C reduction. The guideline specifically states: "In patients with clinical ASCVD who are judged to be very high risk and considered for PCSK9 inhibitor therapy, adding ezetimibe to maximally tolerated statin therapy should be considered before adding a PCSK9 inhibitor" 5. This positioning makes ezetimibe a cost-effective step before escalating to PCSK9 inhibitors that cost $400 to $600 per month.

Ezetimibe vs. PCSK9 Inhibitors: A Cost Perspective

The financial contrast between ezetimibe and PCSK9 inhibitors (evolocumab, alirocumab) is stark. A year of generic ezetimibe costs roughly $48 to $180 out of pocket. A year of evolocumab (Repatha) costs approximately $5,850 at list price, even after recent price reductions 9.

When Ezetimibe Is Enough

For patients whose LDL-C is 10% to 25% above goal on a maximally tolerated statin, adding ezetimibe will often close the gap. The average additional LDL-C reduction of 23% (on top of statin therapy) documented in IMPROVE-IT brings many patients below the 70 mg/dL threshold recommended for secondary prevention 8.

When a PCSK9 Inhibitor Becomes Necessary

Patients with familial hypercholesterolemia or those needing greater than 50% additional LDL-C reduction beyond maximally tolerated statin therapy may require a PCSK9 inhibitor. Even in these cases, most insurance plans require documented trial of ezetimibe before approving a PCSK9 inhibitor. Having ezetimibe on your medication list is essentially a prerequisite for accessing more expensive therapies.

Common Mistakes That Increase Ezetimibe Costs

Several avoidable errors lead patients to pay more than necessary for this inexpensive drug.

Filling Brand Instead of Generic

If your prescription reads "Zetia" and your state requires brand dispensing when a brand name is written, you could pay 30 to 50 times more than the generic price. Ask your prescriber to write "ezetimibe" or check the "substitution permitted" box.

Not Comparing Pharmacy Prices

A 2024 USC Schaeffer Center analysis found that cash prices for the same generic drug can vary by 500% across pharmacies within the same ZIP code 10. Spending 60 seconds checking a discount tool before filling can save $5 to $15 per fill.

Assuming Insurance Is Always Cheaper

For very low-cost generics, your insurance copay ($5 to $15) can exceed the discount card price ($3.50 to $8). Pharmacists are allowed to tell you which option is cheaper if you ask. Some states have enacted "gag clause" bans that prohibit insurers from preventing pharmacists from sharing this information 11.

Skipping the Medication Entirely

Some patients stop ezetimibe because they perceive it as "not worth the cost," even at $5 to $10 per month. IMPROVE-IT demonstrated a 6.4% relative risk reduction in major cardiovascular events over 7 years, and the NNT (number needed to treat) was 50 8. That reduction comes at a cost of roughly $0.15 to $0.50 per day.

How to Switch From Brand Zetia to Generic

If you are still taking brand-name Zetia, the switch is straightforward. Generic ezetimibe 10 mg tablets are AB-rated by the FDA, meaning they are bioequivalent to brand Zetia in both the rate and extent of absorption.

Steps to Switch

1. Ask your prescriber to send a new prescription for "ezetimibe 10 mg" with generic substitution allowed.
2. If your current prescription already permits substitution, simply ask your pharmacist to fill the generic at your next refill.
3. No dose adjustment or new lab work is needed. Continue your current monitoring schedule.
4. Check an LDL-C level at your next routine visit (usually 4 to 12 weeks after any change) to confirm the generic is performing equivalently.

The 2018 ACC Expert Consensus Decision Pathway supports generic substitution for all AB-rated statins and non-statin lipid-lowering agents, including ezetimibe 5.

Combination Products Containing Ezetimibe

Vytorin (ezetimibe 10 mg/simvastatin) is also available as a generic. If you take both ezetimibe and simvastatin, a combination tablet may simplify your regimen. Generic ezetimibe/simvastatin costs $15 to $30 for a 30-day supply. A newer combination of ezetimibe with atorvastatin (brand name Liptruzet) was discontinued in the U.S. Market due to low uptake but remains available in some international markets. Patients who need both ezetimibe and atorvastatin take them as separate tablets.

Bempedoic acid/ezetimibe (Nexlizet) is a branded combination that costs significantly more ($400 to $500/month) but may be appropriate for statin-intolerant patients needing dual non-statin therapy 12.